"Messy compromise" on combo SPCs in EU could increase thickets and litigation
This article was originally published in SRA
Executive Summary
More legal disputes between originators and generics companies could ensue if the Court of Justice of the European Union upholds the opinion1 of one of its advocates general on whether companies can get supplementary protection certificates on their combination drugs, according to one legal expert familiar with the case.